Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 10/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770522 | 0.91 | NPC1 (0.37) | APPMAOBMAOAFFAR1ACHE | |
| SCHEMBL14770525 | 0.91 | APP (0.42) | APPMAOBMAOAFFAR1MMP1 | |
| SCHEMBL14763411 | 0.86 | FFAR1 (0.39) | APPMAOBMAOAFFAR1SMO | |
| SCHEMBL14770523 | 0.84 | FFAR1 (0.36) | APPMAOBMAOAFFAR1 | |
| SCHEMBL14770518 | 0.82 | NPC1 (0.40) | APPMAOBFFAR1 | |
| SCHEMBL14770519 | 0.81 | MAPK1 (0.38) | — | |
| SCHEMBL14770571 | 0.78 | KMT2A (0.46) | APPMAOBMAOAFFAR1ACHE | |
| SCHEMBL12065313 | 0.77 | FFAR1 (0.42) | MAOBMAOAFFAR1 | |
| SCHEMBL12066059 | 0.77 | MAOB (0.39) | APPMAOBMAOAFFAR1MMP1 | |
| SCHEMBL12066068 | 0.75 | MAOB (0.40) | APPMAOBMAOAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | APP 2799/4885MAOB 2158/4885MAOA 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.